Adial Pharmaceuticals, Inc. Grants 307,814-Share Stock Option to New Employee

What Happened

• Adial Pharmaceuticals, Inc. announced on Aug. 19, 2026 that it granted an option to purchase 307,814 shares of common stock to an individual as a material inducement to join the company. The option was approved by the Compensation Committee and granted outside the company’s equity incentive plans under Nasdaq’s employment inducement exception.

Key Details

• Option size: 307,814 shares.
• Exercise price: $5.76 per share (closing price on Aug. 19, 2026).
• Term and vesting: 10-year term; vests over four years (25% after one year, then monthly thereafter).
• Registration and approvals: Grant made under Nasdaq Listing Rule 5635(c)(4); option not registered under the Securities Act and issued relying on Section 4(a)(2) and Regulation D exemptions. Shares from exercise cannot be sold in the U.S. without registration or a valid exemption.

Why It Matters

• This grant creates potential dilution of up to 307,814 shares if exercised (proceeds to the company would be about $1.77 million if all options are exercised at $5.76). It signals the company is using equity inducements to attract talent outside existing plans, which requires public disclosure under Nasdaq rules. Investors should note the timing, size, vesting schedule and that the award was granted under registration exemptions, but the filing does not name the recipient or indicate any immediate cash impact.